On Monday, Paris-based French drugmaker Sanofi announced plans to invest more than €1 billion at three facilities in France to create new bioproduction capacity.
The new investment is expected to create more than 500 jobs and significantly strengthen France’s ability to control the production of essential medicines from start to finish, the company stated. According to Sanofi, this plan increases the amount Sanofi has committed to major projects in France since the Covid-19 pandemic to over €3.5 billion.
In Vitry-sur-Seine, Sanofi wants to invest €1 billion to build a new facility that will double the site’s monoclonal antibody production capacity, where several biologics in development amongst Sanofi’s pipeline of drugs for the treatment of chronic obstructive pulmonary disorder (COPD), asthma, multiple sclerosis or type 1 diabetes, could be produced.
At the Le Trait site in Normandy, Sanofi plans to invest €100 million to expand the capacity for biologics formulation, filling, device assembly and packaging, supporting the launch of future biologics and vaccines, as well as and the further growth of existing biologics production.
In Lyon Gerland, €10 million are to be invested to locate the production of TZield, a biologic for type 1 diabetes that Sanofi acquired in April 2023 and which has been manufactured outside Europe, in France.
Source: chemanager-online.com
Politico’s Agency IQ reported earlier this month that, due to the Trump administration’s laying off of thousands of staffers, the FDA risked hitting a “trigger,” whereby the FDA could be required to refund industry fees if spending by the agency falls below a certain level.
Pharmaceutical companies are demanding changes in European regulation as looming tariffs implemented by US President Donald Trump “threaten” billions of planned pharma investments on the continent. A group of 32 pharma companies sent a letter to European Commission (EC) President Ursula von der Leyen listing requests to avoid an exodus of operations.
Christian Boehringer, Chairman of the Shareholders’ Committee since 2007, has decided to step down from his position as of June 30, 2025. The Shareholders’ Committee has appointed Hubertus von Baumbach, currently Chairman of the Board of Directors, as his successor from July 1, 2025.
